Tagrisso with chemotherapy approved in EU as new 1st-line treatment for patients with EGFR-mutated advanced lung cancer
AstraZeneca’s Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy has been approved in the European Union (EU) for the 1st-line treatment of adult patients with advanced epidermal growth factor receptor-mutated (EGFRm) …